comparemela.com

Latest Breaking News On - William fantegrossi - Page 1 : comparemela.com

PharmAla Data to be Published in ACS Chemical Neuroscience

Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research into Psychedelics ConferenceVANCOUVER, British Columbia, Feb. 20, 2024 (GLOBE NEWSWIRE) PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that

United statesNew orleansBritish columbiaUnited kingdomHarpreet kaurNick kadyshNicholas kadyshWilliam fantegrossiJames gauldA path to novel mental health therapiesNeither the canadian securities exchangeUniversity of waterlooPharmala biotech holdings incInternational society for researchUniversity of arkansasRegulation services provider

PharmAla Receives First Office Action for PharmAla-1 PCT

PharmAla has recieved a positive First Office Action on its novel P-1 Molecule from the Patent Cooperation Treaty.

British columbiaUnited kingdomWilliam fantegrossiNicholas kadyshNick kadyshFirst office actionNeither the canadian securities exchangePharmala biotech holdings incUniversity of arkansasUniversity of windsorRegulation services providerAla biotech holdingsPatent cooperation treatyPrior artCentral nervous systemSmall molecules

PharmAla Receives First Office Action for PharmAla-1 PCT Filing

PCT Examiner Finds Molecule to be both Novel and Inventive VANCOUVER, British Columbia, Sept. 25, 2023 PharmAla Biotech Holdings Inc. , a biotechnology company focused on the research,.

United kingdomBritish columbiaWilliam fantegrossiNicholas kadyshNick kadyshUniversity of windsorUniversity of arkansasFirst office actionPharmala biotech holdings incNeither the canadian securities exchangeRegulation services providerFinds moleculeAla biotech holdingsPatent cooperation treatyPrior artCentral nervous system

PharmAla Files Patent for Novel MDXX Molecule PharmAla-1

Patent Filing Follows Year of Preclinical Research, Academic PublicationVANCOUVER, British Columbia, July 31, 2023 PharmAla Biotech Holdings Inc. , a biotechnology company focused on the.

United kingdomBritish columbiaNew south walesWilliam fantegrossiNicholas kadyshHarpreet kaurNick kadyshPharmala biotech holdings incNeither the canadian securities exchangePatent filing follows year of preclinical researchResearch for pharmala biotechUniversity of arkansasUniversity of windsorUniversity of sydneyRegulation services providerPatent filing follows year

PharmAla Files IP Protection For Novel MDXX Molecule: Viability As Autism Spectrum Treatment - Pharmala Biotech Hldgs (OTC:PMBHF)

Canadian biotech company PharmAla Biotech Holdings (OTC: PMBHF) has filed a patent covering composition of matter of Novel Chemical Entity (NCE) PharmAla-1. 

New south walesNick kadyshWilliam fantegrossiHarpreet kaurSciences in profUniversity of windsorUniversity of arkansasUniversity of sydneyPharmala biotechNovel chemical entityMedical sciencesEntactogens and classical psychedelicsNew publishedAutism spectrum disorder

vimarsana © 2020. All Rights Reserved.